Replimune Group, Inc. (NASDAQ: REPL) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Replimune Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.69, Replimune Group, Inc. trades at 10.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -157.8%, return on invested capital of -80.9% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 0.62 and a current ratio of 7.11. Over the past 52 weeks the share price ranged from $1.50 to $23.54, with a beta of 0.93.
Replimune Group, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.